Chronic Disease Diabetes Events Hypertension 
Today's Hospitalist
JUNE 7, 2025
THE BLOCKBUSTER GLP-1 receptor agonists are a transformative class of medications increasingly tied to better outcomes across a variety of conditions and organ systems, not just in patients with obesity and type 2 diabetes. Published in May 2024, the FLOW trial , for instance, looked at patients with diabetes and advanced kidney disease.
GeriPal
OCTOBER 17, 2024
He was describing his, like, 87 year old grandma who was placed on a low salt diabetic diet. So I have a two and a half year old, and during my last pregnancy, I had gestational diabetes. If they’re frail, if they’re falling, if they have cognitive impairment, they’re at higher risk of adverse drug events.
Expert insights. Personalized for you.
65 
Let's personalize your content